))
Integrating Blood-Based Biomarkers for Alzheimer’s Risk Assessment
Manage episode 461543439 series 3635266
Контент предоставлен Quest Diagnostics®. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией Quest Diagnostics® или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
In this episode of Results are In by Quest Diagnostics, Amanda Benson is joined by Dr. Michael Racke, Medical Director for Neurology at Quest Diagnostics, to discuss the groundbreaking role blood-based biomarkers play in assessing Alzheimer’s disease risk. Dr. Racke shares his expert insights on how these biomarkers are revolutionizing early risk detection and diagnosis, offering primary care physicians a proactive tool to identify Alzheimer’s before cognitive symptoms appear. From the evolution of Alzheimer's diagnostics to the practical application of plasma-based tests, Dr. Racke explains how integrating these tests into routine health visits can enable earlier interventions and better patient outcomes. He also discusses how blood-based biomarkers, in conjunction with digital cognitive assessments, are improving the sensitivity of Alzheimer’s screenings. This episode is a must-listen for anyone interested in the future of Alzheimer’s diagnostics and the power of early detection in cognitive health.
Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics
LinkedIn @QuestDiagnostics
Presented by Quest Diagnostics
www.questdiagnostics.com
2 эпизода
Поделиться
